Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Blockbuster weight loss drugs can help treat ailments as disparate as addiction, blood clotting, and dementia – but they also come with risks that might give some patients pause, a landmark new ...

The U.S. government targets Novo Nordisk's drugs, including Ozempic and Wegovy, for Medicare price negotiations in 2027.